Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas

This publication has 21 references indexed in Scilit:

• Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
  JNCI: Journal of the National Cancer Institute, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
  JNCI: Journal of the National Cancer Institute, 2000
• Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast
  The American Journal of Pathology, 1999
• Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines
  Oncogene, 1998
• PTEN mutations in gliomas and glioneuronal tumors
  Oncogene, 1998
• Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
  Nature Genetics, 1997
• PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
  Science, 1997